Sarepta Therapeutics Inc  

(Public, NASDAQ:SRPT)   Watch this stock  
Find more results for NASDAQ:AVII
13.24
-0.23 (-1.71%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.09 - 13.56
52 week 11.33 - 40.00
Open 13.35
Vol / Avg. 676,805.00/743,041.00
Mkt cap 546.96M
P/E     -
Div/yield     -
EPS -3.38
Shares 41.31M
Beta 0.91
Inst. own 60%
May 7, 2015
Q1 2015 Sarepta Therapeutics Inc Earnings Release - 9:30AM EDT - Add to calendar
Apr 1, 2015
Sarepta Therapeutics Inc. Appoints Edward Kaye, M.D., as Interim CEO and Management Update Conference Call - Webcast
Mar 12, 2015
Sarepta Therapeutics Inc at Barclays Healthcare Conference - Webcast
Mar 9, 2015
Sarepta Therapeutics Inc at ROTH Conference
Mar 2, 2015
Sarepta Therapeutics Inc at Cowen Health Care Conference - Webcast
Feb 26, 2015
Q4 2014 Sarepta Therapeutics Inc Earnings Release
Feb 26, 2015
Q4 2014 Sarepta Therapeutics Inc Earnings Call - Webcast
Feb 24, 2015
Sarepta Therapeutics Inc at RBC Healthcare Conference
Feb 23, 2015
Sarepta Therapeutics Inc at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day
Feb 11, 2015
Sarepta Therapeutics Inc at Leerink Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -164503.70% -1391.71%
Operating margin -165637.00% -1371.21%
EBITD margin - -1313.34%
Return on average assets -58.02% -46.30%
Return on average equity -66.74% -54.88%
Employees 204 -
CDP Score - -

Address

SUITE 415, 215 FIRST STREET
CAMBRIDGE, MA 02142
United States - Map
+1-617-2744000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Sarepta Therapeutics Inc. (Sarepta), formerly AVI BioPharma, Inc., is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company has classified its drug development programs as Duchenne Muscular Dystrophy (DMD) and Infectious Disease Programs. The Company�s Duchenne muscular dystrophy (DMD) is primarily focused on its lead product candidate, Eteplirsen. The Company has completed a Phase IIb clinical trial for Eteplirsen. The Company, under its infectious disease programs, is primarily focused on development of a drug candidate for the Marburg hemorrhagic fever virus. The Company�s infectious disease programs is largely funded and supported by the U.S. Department of Defense (DoD).

Officers and directors

Edward M. Kaye M.D. Interim Chief Executive Officer, Chief Medical Officer
Age: 65
Bio & Compensation  - Reuters
Sandesh Mahatme Chief Financial Officer, Senior Vice President, Chief Accounting Officer
Age: 49
Bio & Compensation  - Reuters
David Tyronne Howton Senior Vice President, General Counsel, Corporate Secretary
Age: 42
Bio & Compensation  - Reuters
Jayant Aphale Ph.D. Senior Vice President - Technical Operations
Age: 53
Bio & Compensation  - Reuters
M. Kathleen Behrens Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
Anthony R. Chase Independent Director
Age: 60
Bio & Compensation  - Reuters
Gil Price M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Hans Wigzell M.D., Ph.D. Independent Director
Age: 76
Bio & Compensation  - Reuters
William A. Goolsbee Non-Executive Independent Director
Age: 60
Bio & Compensation  - Reuters